about
P1889
Chronic treatment with zinc and antidepressants induces enhancement of presynaptic/extracellular zinc concentration in the rat prefrontal cortexAntidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway.Development and validation of an anodic stripping voltammetric method for determination of Zn(2+) ions in brain microdialysate samples.Stress-induced alterations in 5-HT1A receptor transcriptional modulators NUDR and Freud-1Alterations of Bio-elements, Oxidative, and Inflammatory Status in the Zinc Deficiency Model in Rats.Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action.Study of the Serum Copper Levels in Patients with Major Depressive Disorder.The serum zinc concentration as a potential biological marker in patients with major depressive disorder.Zinc as a marker of affective disorders.Oxidative stress markers in affective disorders.The level of the zinc homeostasis regulating proteins in the brain of rats subjected to olfactory bulbectomy model of depression.Olfactory bulbectomy-induced changes in phospholipids and protein profiles in the hippocampus and prefrontal cortex of rats. A preliminary study using a FTIR spectroscopy.Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats.Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile.Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.Decreased serum zinc concentration during depressive episode in patients with bipolar disorder.Zinc-induced adaptive changes in NMDA/glutamatergic and serotonergic receptors.The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test.Intraperitoneal zinc administration increases extracellular zinc in the rat prefrontal cortex.The role of the GPR39 receptor in zinc deficient-animal model of depression.The involvement of the GPR39-Zn(2+)-sensing receptor in the pathophysiology of depression. Studies in rodent models and suicide victims.Antidepressant-like activity of zinc: further behavioral and molecular evidence.Chronic unpredictable stress-induced reduction in the hippocampal brain-derived neurotrophic factor (BDNF) gene expression is antagonized by zinc treatment.Zinc transporters protein level in postmortem brain of depressed subjects and suicide victims.Early lifetime zinc supplementation protects zinc-deficient diet-induced alterations.Zinc deficiency in rats is associated with up-regulation of hippocampal NMDA receptor.Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study.Evaluation of oxidative status and depression-like responses in Brown Norway rats with acute myeloid leukemia.Lack of persistent effects of ketamine in rodent models of depression.Lipid Peroxidation and Immune Biomarkers Are Associated with Major Depression and Its Phenotypes, Including Treatment-Resistant Depression and Melancholia.Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts.The serum concentration of copper in bipolar disorder.The role of zinc deficiency-induced changes in the phospholipid-protein balance of blood serum in animal depression model by Raman, FTIR and UV-vis spectroscopy.Repeated co-treatment with antidepressants and risperidone increases BDNF mRNA and protein levels in rats.Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder.Qualitative and quantitative changes in phospholipids and proteins investigated by spectroscopic techniques in animal depression model.Phospholipid-protein balance in affective disorders: Analysis of human blood serum using Raman and FTIR spectroscopy. A pilot study.Thiobarbituric Acid-Reactive Substances: Markers of an Acute Episode and a Late Stage of Bipolar Disorder.The serum concentration of magnesium as a potential state marker in patients with diagnosis of bipolar disorder.The serum magnesium concentration as a potential state marker in patients with unipolar affective disorder.
P50
Q34466775-E97DCA68-843D-41C9-8400-0BD73B06E281Q34978637-F48BC1DD-1318-40C7-BDF0-0F0ADE521C56Q35154344-F631F021-DAAD-465B-8B4D-846B19E6EEF0Q35887982-6EEEB252-55F6-42E8-B057-69BE9418471DQ36431389-E90ABCAF-5D42-4E7B-9E7F-D3E14775E7FAQ37344554-04235C11-8D29-404E-BAA7-AF249ABA373FQ37385662-B24A4214-BB70-4012-9F91-F8AFB52D008EQ37578455-FA9C8902-CD59-4C8D-B30F-0193DFB3586BQ38189552-B519DADD-7231-4516-BCCF-EE49BF73303EQ38189557-9DD437D8-A901-4507-A1F4-871DD99D7F14Q38291152-4F7A9716-E55C-4965-8D1B-57ADFF22F2B7Q38293713-7695C0D3-B092-4749-9286-D29BE9D509AAQ38298300-58AB9137-DA31-420A-9FC9-A62553B16EE2Q38839861-71ACCC53-41C7-4532-A6C4-E77BCC5335E3Q39302802-BB26D88D-C9D9-4B63-81FA-23CE95EF47FDQ40352847-202E3A2A-CBF8-4DAF-8A5E-506B44AB7073Q43191744-71BBE8B5-3199-4135-82FB-EB7E07347892Q43231289-937CCE74-0661-49B2-B428-C86781180E87Q43473468-81C57B0E-210B-49E0-8C6D-45A76D38D2B2Q43913239-FE0D52B0-4318-4AF0-9E26-368A1E42A7A9Q43965285-37BA0AA4-E798-4CA3-968F-1A5AB3C66B6AQ44207918-95A67309-5993-4194-B6F0-D7C063507EE0Q44669675-3BCAADA3-14E1-466A-869D-D63FE1DF0140Q45153786-BF706947-178A-464F-9EE1-2ED2F23A9ECEQ45373076-66C1DE37-C5EF-47AD-9F87-E46E83A0E41FQ45764818-00F68F77-9621-4227-98AA-C58261BCCA5AQ46091966-15FC59F0-7FB0-4F38-8520-391982DF0275Q46096873-3D341A53-1956-42B5-AF6A-CA5300425A83Q46610466-D234EF01-B2B6-4B56-AFA3-4F4C9C9054A5Q47719124-07E10401-D39B-4CE1-8A3B-1285DF6E0F46Q47779155-4B27585B-2C1D-4A7F-A39D-1E372D7F9DF7Q47779454-3CC7F2B4-78B3-4EFC-AF68-0D370B5640CFQ47786103-45E2056D-DB9C-44F5-9B67-AEA362B73DCFQ47853531-0782E967-D6E0-4A38-B8EE-C3D8B62A622DQ47995947-FDDB6ACA-06E7-4744-B5E8-676911ADD55AQ47998532-B7D37B56-53D0-4F9D-8FF1-DF1222D192F9Q48005127-1813F733-9DBF-4784-A9D8-324C51D9656FQ48059768-A2E4BD53-D58A-4E42-9378-97EAF9FD2D4FQ48063156-31F99AC2-2476-4035-BD44-57F87DF4CCF8Q48063160-914E1AC7-EF06-41F3-8B4C-F46CEDEFEA5D
P50
description
Assistant at Institute of Pharmacology, Polish Academy of Sciences
@en
Pools onderzoekster
@nl
chercheuse en neurobiologie et pharmacologie
@fr
investigadora polaca
@ast
investigadora polaca
@es
name
Magdalena Sowa-Kućma
@ast
Magdalena Sowa-Kućma
@ca
Magdalena Sowa-Kućma
@cs
Magdalena Sowa-Kućma
@de
Magdalena Sowa-Kućma
@en
Magdalena Sowa-Kućma
@es
Magdalena Sowa-Kućma
@fr
Magdalena Sowa-Kućma
@ga
Magdalena Sowa-Kućma
@gl
Magdalena Sowa-Kućma
@hr
type
label
Magdalena Sowa-Kućma
@ast
Magdalena Sowa-Kućma
@ca
Magdalena Sowa-Kućma
@cs
Magdalena Sowa-Kućma
@de
Magdalena Sowa-Kućma
@en
Magdalena Sowa-Kućma
@es
Magdalena Sowa-Kućma
@fr
Magdalena Sowa-Kućma
@ga
Magdalena Sowa-Kućma
@gl
Magdalena Sowa-Kućma
@hr
altLabel
Magdalena Jolanta Sowa-Kućma
@pl
Magdalena Sowa - Kućma
@pl
Magdalena Sowa
@en
Magdalena Sowa
@fr
Sowa-Kućma, Magdalena Jolanta
@pl
prefLabel
Magdalena Sowa-Kućma
@ast
Magdalena Sowa-Kućma
@ca
Magdalena Sowa-Kućma
@cs
Magdalena Sowa-Kućma
@de
Magdalena Sowa-Kućma
@en
Magdalena Sowa-Kućma
@es
Magdalena Sowa-Kućma
@fr
Magdalena Sowa-Kućma
@ga
Magdalena Sowa-Kućma
@gl
Magdalena Sowa-Kućma
@hr
P214
P106
P1207
n2012060087
P1412
P1559
Magdalena Sowa-Kućma
@pl
P1695
P1889
P1960
ane1nEcAAAAJ
P2013
magdalena.sowakucma
P21
P213
0000 0003 7380 8484
P214
P27
P31
P3124
P496
0000-0001-5956-7229
P6634
magdalena-sowa-kućma-0476a014